Funding
Vaccination biotech Vaxxas raises $49 million Series D, cuts C-suite amid broader layoffs
Needle-free vaccination delivery scaleup Vaxxas has raised $49.2 million in a Series D, but cut 10% of its workforce, including a clear out of its executives. The University of Queensland spin out has moved founding CEO David Hoey, who’s been on leave for the past three months, into a strategic adviser role after 13 years… Read more »
